Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 480

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 480
---
989 |
| Other assets                                             |    841 |
| Total  assets held for sale                              | 13,489 |
| Liabilities                                              |        |
| Llease liabilities                                       |    112 |
| Non-current provisions and other non-current liabilities |    204 |
| Accounts payable                                         |    797 |
| Current provisions and other current liabilities         |    570 |
| Other liabilities                                        |    448 |
| Total liabilities related to assets held for sale        |  2,131 |

In accordance with IFRS 5, the Opella held for sale asset group, and the related liabilities, have been measured at the lower of

carrying amount and fair value less costs to sell. This valuation did not result in the recognition of any impairment.

The table below details the main items presented within Net income from discontinued operations :

| (€ million)                                                             |  2024 |  2023 |  2022 |
| Net sales                                                               | 5,031 | 4,884 | 4,781 |
| Operating income                                                        |   305 |   915 |   494 |
| Income before tax and investments accounted for using the equity method |   288 |   902 |   485 |
| Income tax expense                                                      |  -240 |  -585 |   -97 |
| Net income from discontinued  operations (Opella)                       |    64 |   338 |   401 |

Net income from the Opella discontinued operation was € 274million lower in 2024 than in 2023. This year-on-year change

reflects in particular the acceleration in 2024 of the transformational project to create the standalone Opella entity - transaction

costs incurred in 2024 in respect of the proposed Opella transfer - and changes in gains from asset divestments within the Opella

scope between the two periods.

In addition, net income from the Opella discontinued operation for the year ended December 31, 2024 includes a net tax expense

of € 122million relating to the tax cost of the legal restructuring of the Opella scope. For the year ended December 31, 2023, net

income from the Opella discontinued operation includes a € 365million deferred tax liability recognized in respect of investments

in consolidated entities in light of the proposed separation of the Opella business.

The table below presents basic and diluted earnings per share from discontinued operations (Opella, in accordance with IAS